UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000005455
Receipt number R000006368
Scientific Title Adjuvant InterFeron After Curative Resection of HCV-related Hepatocellular Carcinoma in Elderly Patients: a Multicenter Randomized Controlled Trial
Date of disclosure of the study information 2011/04/20
Last modified on 2017/03/26 16:53:41

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Adjuvant InterFeron After Curative Resection of HCV-related Hepatocellular Carcinoma in Elderly Patients: a Multicenter Randomized Controlled Trial

Acronym

iFACT trial

Scientific Title

Adjuvant InterFeron After Curative Resection of HCV-related Hepatocellular Carcinoma in Elderly Patients: a Multicenter Randomized Controlled Trial

Scientific Title:Acronym

iFACT trial

Region

Japan


Condition

Condition

HCV-related hepato cellular carcinoma

Classification by specialty

Hepato-biliary-pancreatic medicine Hepato-biliary-pancreatic surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To investigate and clarify the efficacy and safety of adjuvant interFeron therapy after curative resection of HCV-related hepatocellular carcinoma.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Phase III


Assessment

Primary outcomes

Recurence free survival

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Adjuvant interferon alpha therapy. Three times of 3,000,000 units / a week.

Interventions/Control_2

Close follow-up

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

61 years-old <=

Age-upper limit

77 years-old >=

Gender

Male and Female

Key inclusion criteria

1) Ages between 61 and 77 years old
2) Primary HCC or recurrent HCC more than two years after previous therapy
3) Classical HCC
4) HCV chronic hepatitis or cirrhosis
5) No extrahepatic lesions
6) Fine or moderate organ function fulfilling the following criteria.
7) Child-Pugh score < 8
8) ECOG performance status 0-2
9) CES-D score <16
10) Written informed consent

Key exclusion criteria

1) Positive HBs-Ag
2) Other anticancer treatment or interferon therapy within 3 months before surgery.
3) Specific drug which is forbidden in this trial is needed.
4) Participating in other clinical trial regarding HCC
5) Autoimmune hepatitis, alcoholic hepatitis, etc.
6) Allergy for specific biologics
7) Severe postoperative complications
8) Asthma
9) Diabetes requiring insulin therapy
10) Severe hypertension
11) Heart disease that complicates perioperative treatments
12) Interstitial pneumonia
13) Psychiatric disorder
14) Malignant disease in other organ within 5 years
15) Moderate or severe renal dysfunction (estimated Ccr < 30ml/min)
16) Other reason that an attending doctor considers

Target sample size

300


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Norihiro Kokudo

Organization

Tokyo University Hospital

Division name

Hepato-Biliary-Pancreatic Surgery Division

Zip code


Address

7-3-1, Hongo, Bunkyo-ku, Tokyo, Japan

TEL

03-3815-5411

Email

kihase-tky@umin.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Takeaki Ishizawa

Organization

Tokyo University Hospital

Division name

Hepato-Biliary-Pancreatic Surgery Division

Zip code


Address

7-3-1, Hongo, Bunkyo-ku, Tokyo, Japan

TEL

03-3815-5411

Homepage URL


Email

kihase-tky@umin.ac.jp


Sponsor or person

Institute

Tokyo University Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2011 Year 04 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 03 Month 24 Day

Date of IRB


Anticipated trial start date

2011 Year 04 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2011 Year 04 Month 17 Day

Last modified on

2017 Year 03 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006368


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name